Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr) on these proteins, has proven challenging due to the low cellular abundance of these targets and lack of standardized targeted proteomic methodologies and reagents. These low-level signals account for <1% of cellular phosphorylation; therefore, traditional mass spectrometry-based methods to signaling are limited by sensitivity, reproducibility, and depth of coverage. pTyr events play a pivotal role in cell signaling and are commonly dysregulated in cancer. Profiling the tumor pTyr proteome may reveal therapeutic insights critical to combating disease.
In this Clinical OMICs webinar, our expert speakers will share the latest advances in sample enrichment and preparation, as well as innovations in proteomics technology for targeted peptide quantitation and pathway analysis. Our presenters will introduce the newest panels of SureQuant mass spectrometry kits as well as the novel SureQuant internal standard triggered acquisition methodology for reproducible and sensitive targeted quantitation. Finally, the speakers will describe how applied the novel SureQuant high-density, targeted approach, that leverages isotopically-labeled trigger peptides to reliably quantify several hundred commonly dysregulated pTyr targets in a cohort of human colorectal tumor samples.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelist.